TRA-8, a monoclonal antibody to death receptor 5 induces apoptosis in various cancer cells; however the degree of sensitivity varies from highly sensitive to resistant. We have previously shown resistance to TRA-8 can be reversed using chemotherapeutic agents, but the mechanism underlying this sensitization was not fully understood. Here, we 
Introduction
Limitations in the treatment of breast cancer include drug resistance, poor response rates, and drug toxicity. The first-line therapeutic regimens for metastatic breast cancer include chemotherapeutic agents and biological therapies, used alone or in combination (1) . However, these therapeutic approaches are not sufficient for many patients, and metastatic breast cancer has a 5-year survival rate of only 26% (2) . The current targeted treatments for breast cancer include Tamoxifen or aromatase inhibitors for estrogen receptor positive tumors (~60%) and Herceptin for Her-2/Neu positive tumors (20-25%) (3, 4) . Targeted therapies may be given systemically with less toxicity than conventional chemotherapy, and have the potential to impact metastatic disease.
However, some patients have innate or acquired resistance and a percentage of patients are left without any effective targeted treatment options.
One agent which is being investigated for the targeted treatment of breast cancer is tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2 Ligand) (5) .
TRAIL is a member of the TNF superfamily and has been shown to induce apoptosis via a caspase dependent mechanism in many human breast cancer cell lines by binding to death receptors 4 and 5 (DR4, DR5) (5) (6) (7) (8) . TRAIL activates both extrinsic and intrinsic apoptosis through molecular crosstalk between these pathways (5, 9, 10) . Moreover, while the ligand induces apoptosis in cancer cells, it lacks cytotoxicity against normal cells (5, 11) . Harnessing this ability to stimulate both apoptotic pathways, monoclonal antibodies targeting individual TRAIL death receptors have been developed to provide longer half-lives in vivo and better specificity. TRA-8, which binds directly to DR5, is an Page 4 2/11/2011 agonistic antibody (12) that has been shown to have therapeutic potential in preclinical studies against a variety of cancer types, including breast cancer (12, 13) .
As described by Rahman et al. (5, 14) , breast cancer can be classified into different subtypes, which respond differently to TRAIL or agonistic death receptor antibodies. The majority of breast cancers are of the luminal subtype, which are hormone receptor positive (i.e. they express the estrogen receptor (ER) and/or progesterone receptor (PR)). The subtype with amplified HER-2 expression may be hormone receptor negative or positive. The basal or triple-negative subtype is comprised of tumors lacking ER and PR expression with no amplification of HER-2. Among nine breast cancer cell lines of various subtypes that were examined by our laboratory, each was shown to express DR5; however, only the basal cell lines were sensitive to TRA-8 induced cytotoxicity (13) . The five luminal breast cancer cell lines were less sensitive or resistant to TRA-8. To overcome cellular resistance, we found that chemotherapeutic agents such as doxorubicin or paclitaxel used in combination with TRA-8 produced synergistic cytotoxicity. TRA-8 treatment inhibited the growth of 2LMP (subclone of MDA-MB-231) basal-type breast cancer xenografts in vivo (13) . In other studies, the proteasome inhibitor, bortezomib, was shown to sensitize breast cancer cells to TRAIL-induced cytotoxicity (15, 16) and reduce the metastatic potential of 4T1 murine breast cancer cells in combination with MD5-1, a murine DR5 agonistic antibody (15) . However, additional molecular markers for TRA-8 response and the underlying mechanisms of sensitization by these chemotherapeutic agents are not fully understood. Various regulatory molecules in the apoptotic pathways have been implicated in TRAIL sensitivity and sensitization by chemotherapy, including members of the Bcl-2 and inhibitors of apoptosis (IAP) families Page 5 2/11/2011 (5) , but further characterization of the mechanisms would be useful for developing more efficient means of sensitizing resistant breast cancers.
In the current study, we investigated the mechanisms of sensitization of breast cancer cells (1 basal and 3 luminal cell lines) to TRA-8-induced cytotoxicity by doxorubicin, bortezomib and the small molecule apoptotic modulators, AT-101, BH3I-2'
and AT-406. Doxorubicin and bortezomib sensitized breast cancer cells to TRA-8-induced apoptosis, which was associated with intrinsic pathway activation and reductions in the anti-apoptotic proteins Bcl-XL or XIAP. Small molecule apoptotic modulators were used to investigate the importance of the Bcl-2 and IAP families of proteins in TRA-8 sensitization. AT-101 is a derivative of gossypol, a natural product of cottonseeds, which acts as a BH3-mimetic by binding to Bcl-2, Bcl-XL, Bcl-w and Mcl-1 (17, 18) . BH3I-2' is another BH3-mimietic, which binds to Bcl-2 and Bcl-XL. AT-406, a Smac-mimetic, binds to cellular inhibitor of apoptosis 1 and 2 (c-IAP-1/2), XIAP and livin (19, 20) . These agents provide specific targeting of Bcl-2 and IAP families of proteins, and sensitized breast cancer cells to TRA-8-induced apoptosis via induction of the intrinsic apoptotic pathway. These results suggest that targeting of anti-apoptotic proteins may be valuable for enhancing the efficacy of TRAIL-targeted therapies for the treatment of breast cancer.
Results

Differential cytotoxicity of human breast cancer cell lines after treatment with anti-
DR5 antibody in combination with chemotherapy
Sensitivity to TRA-8 anti-DR5 antibody-induced cytotoxicity alone or in combination with doxorubicin or bortezomib was examined in six human breast carcinoma cell lines. 2LMP cells treated with TRA-8 resulted in a dose-dependent decrease in cell viability with an IC 50 concentration of 1.08 ng/ml (Fig. 1A) . In contrast, the ZR-75-1 cell line had a TRA-8 IC 50 of 387.7 ng/ml. The BT-474, T47D, MDA-MB-453, and ZR-75-30 cell lines were resistant to TRA-8 with no IC 50 observed up to 1,000 ng/ml. This differential response to TRAIL receptor targeted therapy is consistent with previously reported results (13, 21) . 2LMP and ZR-75-1 cells showed similar sensitivities to TRAIL ligand as TRA-8, while BT-474, T47D, MDA-MB-453, and ZR-75-30 cells were similarly TRAIL resistant ( Supplementary Fig. S1 ). Flow cytometry analysis showed that DR5 expression on the surface of these breast cancer cell lines was variable ( Supplementary Fig. S2 ), but the mean fluorescent intensity did not correlate with TRA-8 IC 50 values (r = -0.309, p = 0.551). respectively), but the combination of these two agents resulted in up to 75% cytotoxicity.
To examine the caspase dependence of the combined treatment with TRA-8 and doxorubicin, 2LMP and BT-474 cells were pretreated with the general caspase inhibitor, Z-VAD-FMK. In both 2LMP and BT-474 cells, the caspase inhibitor diminished the cytotoxicity of the combination of TRA-8 and doxorubicin ( Supplementary Fig. S3 ), indicating that sensitization was caspase-dependent. As shown in Figure 1C To further investigate the impact of combination treatment on the intrinsic apoptotic pathway and to identify specific proteins involved in the chemotherapy-induced sensitization, the modulation of members of the Bcl-2 family was examined. In 2LMP cells, the anti-apoptotic protein Bcl-XL was reduced by treatment with TRA-8 alone and in combination with doxorubicin or bortezomib (Fig. 3B) . In ZR-75-1 cells, the individual chemotherapy agents increased Bcl-XL, but combined with TRA-8 the levels We also examined the levels of pro-apoptotic Bcl-2 family members Bad, Bax, Bim, and Noxa ( (Fig. 4C) , while the combination index could not be calculated in the ZR-75-1 cells because the combination did not produce any cytotoxicity above that of TRA-8 alone. Although the interaction between AT-406 and TRA-8 in the T47D cells was synergistic, the cells were resistant to both agents alone and combined there was never more than 40% cytotoxicity ( Supplementary Fig. S7 ). To extend these observations, siRNA was used to knock down XIAP. In BT-474 cells, the (Fig. 4D) and decreased gene expression (data not shown). Knockdown of XIAP sensitized BT-474 cells to TRA-8, leading to a significant increase in cytotoxicity compared to TRA-8 or XIAP siRNA alone or a non-specific siRNA (alone or in combination with TRA-8) (Fig. 4E) . In the T47D cell line, anti-XIAP siRNA did not significantly affect the response to TRA-8 compared to non-specific siRNA, indicating that XIAP knockdown was not sufficient to sensitize these cells to TRA-8-induced cytotoxicity. Thus, it appears that neither the Bcl-2 nor IAP families are exclusively responsible for the sensitization effect. However, sensitization to TRA-8-induced apoptosis was achieved in each breast cancer cell line by targeting at least one of these families of proteins. We then determined the effect of Bcl-2 and IAP inhibition on the intrinsic apoptotic pathway by determining ΔΨm. In 2LMP cells, AT-101 or AT-406 alone produced a decrease in ΔΨm, but there was a significantly larger decrease in the potential with TRA-8 alone or in combination with either compound (Fig. 5B) . In ZR-75-1 and 
Differential regulation of caspase-3 in human breast cancer cells treated with TRA-
8, chemotherapy or apoptotic modulators
To further investigate differences in cytotoxicity in the breast cancer cell lines with combination treatment, we monitored the cleavage of caspase-3 to its active form by flow cytometry. TRA-8 alone and in combination with doxorubicin, bortezomib, AT-101 or AT-406 induced cleavage of caspase-3 in 2LMP cells (Fig. 6) . In ZR-75-1 cells, TRA- 
Discussion
Over the past several years, we and others have examined the effects of TRAIL and TRAIL receptor-targeting antibodies against a variety of human cancer cell lines both in vitro and in vivo (6, (11) (12) (13) 21) . Many reports have demonstrated the activity of TRAIL or TRA-8, an agonistic monoclonal antibody to DR5, used as single agents against certain human breast cancer cell lines; however other breast cancer cell lines were resistant to these treatments. It was later discovered that TRAIL and TRA-8 sensitive breast cancer cell lines were primarily those with a triple negative basal phenotype, while ER+ (luminal phenotype) or HER2 over-expressing cell lines were predominantly resistant (5, 13). We examined whether other cellular markers predicted sensitivity to TRA-8 in resistant breast cancer cell lines and showed that surface expression of DR5, and basal levels of Bcl-2 and IAP proteins did not correlate with sensitivity to TRA-8 ( Supplementary Fig. S2, S5 , and S6). There have been reports that the innate resistance of the luminal cells can be reversed by combination treatment with chemotherapeutic agents or various other agents, such as histone deacetylase inhibitors (12, 25) . We have shown sensitization with doxorubicin and bortezomib in the current study (Fig. 1) . While the luminal subtype clinically has the best prognosis, the development of resistance is still a common problem with node-positive patients having a 10-year overall survival rate of 65% (1, 26) . Enhancing the efficacy of initial chemotherapy with the addition of targeted therapies would be beneficial. (Fig. 3C) . Thus, the overall effect with both chemotherapy agents 
Materials and Methods
Cell Lines and Reagents
The 
Cell Viability Assay
Cells were trypsinized and seeded at 1000 cells/well in Costar 96-well plates in complete media and incubated overnight at 37°C. Cells were pretreated with various doses of drug for 24 h prior to the addition of TRA-8 and incubated for an additional 24 h before assessment of cell viability by measurement of cellular ATP levels using the ATPLite luminescence-based assay (Perkin Elmer, Boston, MA) and a TopCount Luminescence Reader (Packard Instruments, Meriden, CT).
Western Blot Analysis
Cells were plated at 5 x 10 6 cells/ml in complete media and incubated overnight. Proteins were visualized using chemiluminescence reagents (GE Healthcare, Piscataway, NJ) according to manufacturer's instructions.
Mitochondrial Membrane Potential
The mitochondrial membrane potential (ΔΨm) was assessed using JC-1 (5, 5, 6, For siRNA knockout experiments, a two-group student t-test was used to compare the differences in cytotoxicity between treated and untreated control cells.
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